First in Human Study in Healthy Volunteers of Antimicrobial Peptide PL-18 Vaginal Suppositories
Status:
Not yet recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
This is a Single-center, Randomized, Double-blind, Placebo-controlled Phase I Study to
Evaluate the Safety, Tolerability and PK Profiles of Single and Multiple Ascending Doses of
Antimicrobial Peptide PL-18 Vaginal Suppositories.